ClinicalTrials.gg
RecruitingNCT07349550AtWorkUpdated Jan 21, 2026

AtWork: The Relation Between Cognitive Functioning, Common Mental Disorders and Work Functioning

An observational study in Depression - Major Depressive Disorder and Anxiety, sponsored by Norwegian University of Science and Technology. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Norwegian University of Science and Technology · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Depression with a site in Norway — 22 open to participants now, 31 under way, none of them phase 3. Depression · Norway.

Planned enrollment
21st of 28
200 · median 575
Started
2024
with 2 others
Observational
28 of 109
5 open now
Primary completion
2029-08
later than 27 of 30 live
Registered
101st of 109
by date
Lead sponsor
7 of 109
Norwegian University of Science and Technology

Among the 109 studies in Depression with a site in Norway, this one is the 21st largest by planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2024, is one of 28 observational ones, reaches primary completion later than 27 of the 30 other live ones, and was the 101st registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

22 of the 109 studies in Depression with a site in Norway are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Depression with a site in Norway, or all of them as a file.
02

Study summary

Depression and anxiety affects levels of function across different levels like work, increasing levels of sick leave and as well as cognitive functioning. In the current study patients at risk of sick leave with depression and anxiety receive metacognitive therapy and work focus in an ordinary outpatient clinic. Impaired cognitive functioning may also be of importance in the return to work process and degree of sick leave. It is important to get a better understanding of how cognitive functioning is related to sick leave and if it predicts return to work, and if cognitive functioning is changed due to psychological treatment.

Read the detailed description

The study is a naturalistic study exploring cognitive functioning of patients with common mental disorders (CMD) treated with metacognitive therapy and work focused interventions, and changes over time.

Sick leave is common for patients with CMD, also after having completed treatment for CMD. Why patients remain on sick leave after having completed treatment is underexplored. Potential reasons may be that work and sick leave is not addressed during therapy, there could be issues related to the work place, also there may be characteristics related to the patients functioning that is underexplored. In the latter context, little knowledge regarding the relations between cognitive functioning, symptoms of CMD and work functioning. Previous studies have investigated neuropsychological functions in relation to work related stress and stress-related exhaustion, and found worse performance on cognitive tasks compared to healthy controls. Although stress-related exhaustion can be considered a phenomenon related to CMD, there are no studies the investigators are aware of that investigate neuropsychological predictors specifically related to CMD and work functioning. A review from 2022 specifically aimed to identify neuropsychological predictors of vocational rehabilitation outcomes in individuals with MDD specifically, and found no studies. This clearly demonstrates a knowledge gap that this project would fill. E.g., lower cognitive functioning after successful treatment of CMD is related to increased risk of additional sick leave. With this in mind, increasing our knowledge of these variables can help clinicians identify patients at risk for additional sick leave, even after successful treatment. A previous study at the same clinic has identified three subgroups in a sample of patients with CMD at risk of sick leave. The first group was never on sick leave. The second group returned to work after sick leave during or shortly after treatment. In the third group half of the patients remained on sick leave or disability. To better understand characteristics of such subgroups it is relevant to explore standard clinical information given in the patient's journal. This project is mainly, but not exclusively a PhD-project. The time schedule for the project will go beyond the time for the PhD, especially long-time follow-up.

The main aims of the project are the following:

To explore how descriptive variables, CMD symptoms, and cognitive functioning are associated with work functioning (sick leave or risk for sick leave) before treatment. And what is the interplay between symptoms, cognitive profiles and sick leave.

To explore whether cognitive functioning can predict outcomes of both symptoms of CMD and degree of sick leave, and if cognitive functioning changes through MCT and work focused interventions.

03

Conditions studied

  • Depression - Major Depressive Disorder
  • Anxiety

Browse trials for

Keywords

  • Metacognitive therapy
  • Work focus
  • Depression
  • Anxiety
  • Sick leave
04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 200 is above the median of 175 across 1,261 observational studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 47 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients referred with depression and/or anxiety disorders at risk of sick leave.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of depression and/or anxiety,
  • at risk of sick leave

Exclusion criteria

Exclusion Criteria:

  • personality disorders cluster A or B,
  • ongoing substance abuse,
  • symptoms of psychosis,
  • acute suicidality,
  • serious somatic disorders
06

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients referred with depression and/or anxiety and at risk of sick leave

    Patients referred with depression and/or anxiety and at risk of sick leave

07

What researchers measure

Primary outcomes

  1. Patient Health Questionnaire-9 (PHQ-9)

    Measure of depressive symptoms (PHQ-9) range 0-27 higher scores indicate higher degree of depressive symptoms

    Time frame: Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up

  2. Generalized Anxiety Disorder (GAD-7)

    Anxiety symptoms (GAD-7) range 0-21 higher scores indicating higher degree of anxiety symptoms

    Time frame: Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up

  3. Changes in sick leave

    Sick leave is collected from national register data measured in number of days of sick leave.

    Time frame: Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — Due to ethical considerations as this is a clinical study that includes patients with depression and/or anxiety at risk of sick leave, information will not be shared

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Aug 2029, 67 months after the start.

Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 67 months is above that.

Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jan 20, 2026
StartActual
Jan 1, 2024
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 1, 2032
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07349550
Collaborators
Diakonhjemmet Hospital, The Research Council of Norway
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Jan 1, 2024
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2032 (estimated)
Last update
Jan 21, 2026

Study contacts

Odin Hjemdal, PhD
Contact
odin.hjemdal@ntnu.no
+4773597889

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion